A phase 2 study of ONC201 in recurrent/refractory metastatic breast cancer and advanced endometrial carcinoma

被引：0
|
作者：
Gatti-Mays, Margaret E.
Greer, Yoshimi
Steinberg, Seth
Soltani, Sanaz
Collins, Julie
Olson, Michelle
Ojemuyiwa, Michelle
Annunziata, Christina
Lee, Jung-Min
Nunes, Ana
Lipkowitz, Stan
Zimmer, Alexandra
机构：
[1] NCI, Womens Malignancies Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, NIH, Bethesda, MD 20892 USA
[3] Walter Reed Natl Mil Med Ctr, Murtha Canc Ctr, Bethesda, MD USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-04
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
    Yuan, Xun
    Kho, Dhonghyo
    Xu, Jing
    Gajan, Ambikai
    Wu, Kongming
    Wu, Gen Sheng
    ONCOTARGET, 2017, 8 (13) : 21626 - 21638
  • [22] ONC201 and Its Potent Analogues Disrupt Mitochondrial Metabolic Function in Triple Negative Breast Cancer
    Fennell, Emily
    Aponte-Collazo, Lucas
    Graves, Paul
    Herring, Laura
    Iwanowicz, Ed
    Holmuhamedov, Ekhson
    Graves, Lee
    FASEB JOURNAL, 2020, 34
  • [23] A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Leighl, Natasha B.
    Dent, Susan
    Clemons, Mark
    Vandenberg, Theodore A.
    Tozer, Richard
    Warr, David G.
    Crump, R. Michael
    Hedley, David
    Pond, Gregory R.
    Dancey, Janet E.
    Moor, Malcolm J.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (01) : 87 - 92
  • [24] A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Natasha B. Leighl
    Susan Dent
    Mark Clemons
    Theodore A. Vandenberg
    Richard Tozer
    David G. Warr
    R. Michael Crump
    David Hedley
    Gregory R. Pond
    Janet E. Dancey
    Malcolm J. Moore
    Breast Cancer Research and Treatment, 2008, 108 : 87 - 92
  • [25] ONC201 sensitizes resistant breast cancer cells to TRAIL through death receptor 5 upregulation
    Ralff, Marie D.
    Wagner, Jessica
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2018, 78 (13)
  • [26] Antitumor efficacy of combination treatment with ONC201 and enzalutamide or darolutamide in metastatic castration-resistant prostate cancer
    Wu, Jinxuan Laura
    Zhou, Lanlan
    Zhang, Leiqing
    Huntington, Kelsey E.
    Carneiro, Benedito
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2022, 82 (12)
  • [27] First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
    Stein, Mark N.
    Mayer, Tina M.
    Moss, Rebecca Anne
    Silk, Ann W.
    Chan, Nancy
    Haffty, Bruce George
    DiPaola, Robert S.
    Beckett, Yasmeen
    Bentlyewski, Edward
    Zheng, Ling
    Fang, Bruno
    Allen, Joshua
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
    Lim, Bora
    Peterson, Christine B.
    Davis, Alexander
    Cho, Elin
    Pearson, Troy
    Liu, Huey
    Hwang, Minha
    Ueno, Naoto Tada
    Lee, Jangsoon
    BIOMEDICINES, 2021, 9 (10)
  • [29] A phase II study of leuprolide in advanced/recurrent endometrial cancer
    Covens, A
    Thomas, G
    Shaw, P
    Ackerman, I
    Osborne, R
    Lukka, H
    Carey, M
    Franssen, E
    Roche, K
    GYNECOLOGIC ONCOLOGY, 1997, 64 (01) : 126 - 129
  • [30] Preclinical evaluation of imipridone ONC201 in triple negative breast cancer identifies predictive biomarkers and combinatorial opportunities
    Lim, Bora
    Lee, Jangsoon
    Liu, Huey
    Pearson, Troy
    Coffer, Larry
    Tripathy, Debu
    Ueno, Naoto T.
    CANCER RESEARCH, 2017, 77
12345